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Objectives: A cross-sectional study on prevalence of HBV and HDV infection, risk factors and
genotype  distribution of HBV infection was conducted among 848 HIV-infected patients in
Mato Grosso do Sul, Central Brazil.
Methods: Serum samples of 848 participants were tested for hepatitis B surface antigen
(HBsAg),  hepatitis B core antibody (anti-HBc) and hepatitis surface antibody (anti-HBs).
HBsAg  positive samples were tested for anti-HBc IgM, HBeAg, anti-HBe, anti-HCV, and
total  anti-HDV. HBsAg and anti-HBc positive were subjected to DNA extraction. Viral DNA
was ampliﬁed by semi-nested PCR for the regions pre-S/S and then puriﬁed and geno-
typed/subgenotyped by direct sequencing. Student’s t-test, chi-square test and Fisher’s exact
test were used to compare variables and to evaluate association between HBV positivity
(deﬁned  as anti-HBc and/or HBsAg positivity) and risk factors.
Results:  Among the 848 HIV infected patients investigated 222 had serological markers
of  HBV infection. The prevalence rate of HIV-HBV coinfection was  2.5% (21/848; 95% CI:
1.4–3.5%);  484 (57.1%) patients were susceptible for HBV infection. There were no cases ofanti-HDV positive and only one (0.1%) anti-HCV-positive case among the HIV-HBV coin-
 gender, increasing age, family history of hepatitis, use of illicit drug,fected  patients. Maleand  homosexual activity were independent factors associated with HBV exposure. The phy-
logenetic analysis based on the S gene region revealed the presence of genotypes D (76.9%),
F  (15.4%) and A (7.7%) in the study sample.
∗ Corresponding author at: Avenida Senador Filinto Mueller, s/n, CCBS, Cidade Universitária, 79070-900, Campo Grande, MS, Brazil.
E-mail address: zacalusni@yahoo.com.br (S.Z. Freitas).
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Conclusion: This study demonstrates the low prevalence of HIV-HBV infection and also high-
lights the need for early vaccination against HBV as well as testing for HBV, HCV and HDV
in all HIV-infected individuals.
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Introduction
An estimated 34 million people are currently infected with HIV
worldwide, and of these, three million are chronically infected
with  HBV and seven million are coinfected with HCV due to
the  similarity in the transmission routes.1
However, many  factors can inﬂuence and modify these
estimates, such as geographical region, risk groups, age of
infection,  modes of transmission efﬁcacy or efﬁciency of
exposure.  Global prevalence of HIV-HBV coinfection is het-
erogeneous, ranging from 6% to 26%.1,2 In the Central-West
Region of Brazil, scarce information is available on the preva-
lence  of HIV-HBV coinfection and HDV infection. Most of the
studies,  conducted in South and Southeast regions of Brazil,
have  reported HIV-HBV coinfection prevalence, ranging from
2.3%  to 27.3%.3–7 Furthermore, this is the ﬁrst study reporting
the  HBV genotypes in HIV infected individuals in Central-West
Region  of Brazil.
The  survival of HIV infected patients has markedly
improved since the introduction of highly active antiretro-
viral  therapy (HAART) and deaths from AIDS-related causes
have  declined. However, multiple studies have shown that
liver  disease, caused by hepatitis B virus (HBV) and hepati-
tis  C virus (HCV) coinfections, chronic alcoholism, hepatic
tuberculosis or hepatotoxicity associated with antiretrovi-
ral  therapy, has emerged as the leading cause of mortality.8
Evidence has demonstrated that coinfection with HIV signiﬁ-
cantly  alters the natural history of HBV infection, inﬂuencing
disease progression.9,10 HBV coinfection negatively inﬂuences
the  course of HIV infection but this hypothesis remains quite
controversial. The mechanisms by which HBV may  inﬂuence
HIV  infection are poorly understood.9,11
Several viral factors, including HBV genotype and spe-
ciﬁc  viral mutations, have been documented to inﬂuence the
clinical  outcome of HBV infection.12 While HBV genotype A
is  the most common in co-infected individuals, the non-A
genotypes are associated with more  advanced ﬁbrosis. Fur-
thermore,  genotypes B and C were associated with higher viral
loads  in comparison to genotypes A and D.10 Conditions of
selection  pressures including vaccination, antiviral therapy
and  host immune response may  result in the emergence of
viral  variants which may  be associated with progression to
more  severe liver disease.12
Hepatitis Delta virus (HDV) infection has a worldwide dis-
tribution  and infects human already infected by Hepatitis B
virus (HBV). Approximately, 15 million people worldwide are
infected  with HDV and the prevalence of HDV infection varies
greatly  throughout different geographic regions. In Brazil, HDV
is  highly endemic in the Amazonian region, but data in other
13,14regions  from Brazil are scarce.
This study aimed to determine the prevalence of HBV
and  HDV infection, HIV-HBV coinfection and HBV genotype
distribution in HIV-infected patients at a referral center forlsevier Editora Ltda. 
HIV/AIDS, in Campo Grande, Mato Grosso do Sul, Central-West
Region  of Brazil. Additionally, epidemiological data regarding
risk  factors and vaccinal status was assessed.
Materials  and  methods
Study  population
For this cross-sectional study, 848 HIV infected patients were
recruited  from the Esterina Corsini University Hospital of
the  Federal University of Mato Grosso do Sul (HU/UFMS) and
from  the Reference Center of Infectious and Parasitic Diseases
(CEDIP)  in the capital city of Campo Grande, Mato Grosso do
Sul,  Central-West Region of Brazil, between November 2009
and  July 2011. The age of patients ranged from 14 to 87 years
with  a mean of 41.6 years; 483 (57%) were  men  and 365 (43%)
were  women. Participants were classiﬁed as HIV-HBV coin-
fected  if they presented hepatitis B surface antigen (HBsAg)
positive.  Serological evidence of exposure to HBV was  deﬁned
as  anti-HBc positivity. Individuals with previous serological
evidence of HBV vaccination (anti-HBs alone) were excluded
from  the HBV risk factors analysis.
HIV-positive patients, who consented to participate in the
investigation by signing the Instrument of Consent, were  inter-
viewed  using a standard form, which collected information
regarding their sociodemographic data and risk character-
istics  associated with HIV-HBV coinfection. The interviews
were  conducted individually to guarantee full privacy of the
research  participants. Blood samples were collected from all
individuals  and sera were stored at −20 ◦C. This study was
approved by the Ethics Committee (CEP) of the Federal Uni-
versity  of Mato Grosso do Sul.
Serologic  tests
Serum samples of 848 participants were tested for hepatitis B
surface antigen (HBsAg), hepatitis B core antibody (anti-HBc)
and  hepatitis surface antibody (anti-HBs) using enzyme-
linked immunosorbent assay (ELISA) (bioMérieux BV, Boxtel,
The  Netherlands). Patients with results initially reactive to
anti-HBc  or HBsAg were subjected to new blood collection
and  sera were tested in duplicate. HBsAg positive samples
were  tested for anti-HBc IgM, HBeAg, anti-HBe, anti-HCV and
total  anti-HDV by electrochemiluminescence immunoassay
(ECLIA), using the Cobas® e601 analyzer (Roche Diagnostics,
Mannheim, Germany), according to manufacturer’s instruc-
tions.
DNA  extraction  and  ampliﬁcation
Este é um artigo Open Access sob a licença de CC BY-NC-NDHBsAg positive samples were  submitted to DNA extrac-
tion  using the High Pure Viral Nucleic Acid Kit (Roche,
Mannheim, Germany). After precipitation, the pellet was
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Table 1 – Primers used for PCR ampliﬁcation and sequencing.
Primers Nt positiona Sequences
PS1 (sense) Nt 2826-2845 5′-CCA TAT TCT TGG GAA CAA GA-3′
P3 (antisense) Nt 1019-1000 5′-AAA GCC CAA AAG ACC CAC AA-3′
S2 (antisense) Nt 841-819 5′-GGG TTT AAA TGT ATA CCC AAA GA-3′
S22 (antisense) Nt 841-819 5′-GTA TTT AAA TGG ATA CCC ACA GA-3′
PS4 (sense) Nt 3194-3218 5′-ACA CTC ATC CTC AGG CCA TGC AGT G-3′
PS2 (antisense) Nt 143-124 5′-GGT CCC CAG TCC TCG AGA AG-3′
S4 (sense) Nt 416-436 5′-TGC TGC TAT GCC TCA TCT TCT-3′
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ﬁa Nucleotides (nt) are numbered starting at the cleavage site for the
(3221 bp) HBV genotype A genome. HBV, hepatitis B virus; PCR, pol
ried and resuspended in 50 L of elution buffer. The
re-S/S genome region was  partially ampliﬁed by semi-
ested  PCR. The primers used in the ﬁrst round were  PS1
5′-CCATATTCTTGGGAACAAGA-3′, nucleotide position 2826-
845) and P3 (5′-AAAGCCCAAAAGACCCACAA-3′, nucleotide
osition  1019-1000). The ﬁrst round of ampliﬁcation was
erformed with 1 L of DNA and one unit of Taq DNA poly-
erase  (Invitrogen, San Diego, CA, USA) in a ﬁnal volume
f  25 L, under the following conditions: after an initial
enaturation step of 2 min  at 94 ◦C, DNA was  ampliﬁed
sing 30 cycles of 94 ◦C for 30 s, 55 ◦C for 30 s, and 72 ◦C
or  1 min  and 30 s, followed by a ﬁnal elongation step
or  7 min  at 72 ◦C. The second round was  conducted by
sing  one sense primer (PS1) and two antisense primers S2
5′-GGGTTTAAATGTATACCCAAAA-3′, nucleotide position 819-
41), and S22 (5′-GTATTTAAATGGATACCCACAGA-3′, 819-841)
ocated  at the same position on the genome to facilitate
he  ampliﬁcation of all HBV genotypes. The second round
f  ampliﬁcation was  performed in a ﬁnal volume of 50 L,
sing  1 L of the ﬁrst round PCR product, under the follow-
ng  conditions: an initial denaturation step of 3 min  at 94 ◦C,
ollowed  by 30 cycles of 95 ◦C for 30 s, 52 ◦C for 40 s, and 72 ◦C
or  2 min, followed by a ﬁnal elongation step for 7 min  at 72 ◦C.
en  microliters of ampliﬁcation product (∼1200 bp in length)
as  loaded on 2% agarose gels, electrophoresed, stained with
thidium  bromide and visualized under UV light.
ucleotide  sequencing  and  phylogenetic  analysis
ucleotide sequences of the pre S/S region were  deter-
ined by direct sequencing with BigDye Terminator kit
Applied  Biosystems, CA, USA) using speciﬁc HBV primers,
S1,  PS4, S4, S2 and PS2 (Table 1). Sequencing reactions
ere  analyzed on an ABI3730 automated sequencer (Applied
iosystems). HBV sequences determined in this study were
eposited  in GenBank database under accession numbers KF
11239 to KF 111245. Multiple sequence alignment was per-
ormed  with CLUSTAL X program (version 1.63b, December
997;  http://www-igbmc.u-strasbg.fr/BioInfo/ClustalX/) after
ddition of reference sequences representing all known
BV  subgenotypes available at the GenBank. Phyloge-
etic analysis was  performed by Bayesian Inference using
onte  Carlo Markov Chain (MCMC) in MrBayes version
.1.2  algorithm (http://mrbayes.csit.fsu.edu) under the model
f nucleotide substitution GTR++I, selected as the best-
t  model by jModeltest program (http://darwin.uvigo.es/iction enzyme, EcoRI, located in the pre-S2 region of the full-length
se chain reaction.
software/jmodeltest.html). MCMC algorithm was imple-
mented in two independent runs for 1 × 107 generations
with a sample frequency of 100 and a burn-in of 25%
of  the initial trees. Chains convergence was  conﬁrmed
by calculation of Effective Sample Size (ESS) values >200
using  TRACER v1.5 (http://tree.bio.ed.ac.uk/software/tracer/).
The  phylogenetic tree was  visualized using FigTree v1.3.1
(http://tree.bio.ed.ac.uk/software/ﬁgtree/).
Statistical  analysis
Prevalence data and 95% conﬁdence intervals were  calculated.
Student’s t-test (continuous variable), chi-square test and
Fisher’s  exact test (categorical variables) were used to compare
variables  and to evaluate association between HBV infection.
For  the purposes of analysis, a positive identiﬁcation of HBsAg
and/or  anti-HBc markers was  considered an indication of cur-
rent  or previous HBV infection. Vaccinated individuals (only
anti-HBs  reagent; n = 142) were not included in the HBV risk
factors  analysis. These risk factors estimated by odds ratio in
univariate analysis were further analyzed in a stepwise logistic
regression  model to identify possible confounders. Differences
were  considered statistically signiﬁcant when p-values < 0.05.
Statistical  evaluations were performed using EpiInfo (version
3.5.3;  http://wwwn.cdc.gov/epiinfo/) and SPSS (version 11.0;
SPSS Inc., Chicago, USA, 1999).
Results
A total of 848 patients HIV-infected were included in the study.
The  sociodemographic characteristics of the all patients are
summarized  in Table 2.
Among the 848 HIV infected patients investigated, 222
(26.2%;  95% CI: 23.3–29.3%) presented serological markers of
HBV  infection. Among them, 21 (2.5%) were  HBsAg positive,
154  (18.1%) had anti-HBc and anti-HBs markers and 47 (5.5%)
were  anti-HBc alone.
The  prevalence rate of HBV-HIV coinfection was  2.5%
(21/848; 95% CI: 1.4–3.5%) and among these 21 were  HBsAg
positive samples, 3 (14.3%) were HBsAg isolated, HBeAg was
detected  in 7 (33.3%), anti-HBe in 9 (42.9%), while 5 (23.8%)
were  negative for both HBeAg and anti-HBe. Only 1 sample
was  HBsAg plus anti-HBc IgM.
The immune response to HBV vaccine (anti-HBs alone)
among HIV-1 infected individuals was  present in 16.7%
of  the patients (142/848) (Table 3). Data on vaccination
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Table 2 – Sociodemographic characteristics among
HIV-infected patients in Campo Grande, Brazil, 2013
(n  = 848).
Variable n %
Gender
Female 365 43.0
Male  483 57.0
Age  (years)
≤25 55 6.5
26–35  202 23.8
36–45  296 34.9
46–55  207 24.4
>55  88 10.4
Partnership
With  a steady partner 377 44.5
Without a steady partner 471 55.5
Race/ethnicity
White 470 55.4
Brunette skin/Brown 265 31.3
Black 113 13.3
Education level
Illiterate  37 4.4
Primary 446 52.6
Secondary 253 29.8
University 112 13.2
Place of birth
MS  551 65.0
Other states 297  35.0
Family income (minimum wagea)
<1 77 9.1
1–3  635 74.9
≥4  136 16.0
Number of people per household
1  139 16.4
2–4  580 68.4
5–10  123 14.5
>10  6 0.7
Religion
No  religion 117 13.9
Catholic 387 45.6
Evangelical 287 33.8
Others 57 6.7
a Minimum wage: approximately US$ 300.00 per month.
Table 3 – Prevalence of serological markers of HBV infection in 
Sul, Central-West Brazil.
Category Serological marker 
HBV infection
HBsAg 
Alone anti-HBc 
Anti-HBc/anti-HBs 
Any infection marker 
Not exposed, possibly vaccinated Alone anti-HBs 
Not exposed, susceptible Absence of marker 
Total 
a CI, conﬁdence interval. 1 4;1  8(5):473–480
history was  available for 385 HIV-infected participants. Only
169  of them had completed the HBV vaccination schedule (3
doses).  Among them, 141 had no infection marker (anti-HBc
or  HBsAg). Immune response to HBV vaccine (anti-HBs alone)
was  found in 43.2% (61/141) of these individuals.
Among 848 patients, 484 (57.1%) were  susceptible for HBV
infection.  Of them, 77 patients (15.9%) received the complete
vaccination schedule against hepatitis B.
Only one HIV infected patient (0.1%) had both HBV (HBsAg
plus  total anti-HBc positive) and HCV (anti-HCV) coinfection.
Among 21 HBsAg positive patients, none presented anti-HDV
positivity.
The  prevalence of HBV serological markers was  higher in
men  (39.1%) than in women (20.5%), and the difference was
statistically  signiﬁcant (p < 0.05). A signiﬁcant association for
increasing infection rate with increasing age was observed
(Table  4).
The  univariate analysis showed associations between HBV
infection  with male gender, increasing age, having steady
partnership, family history of hepatitis, use of illicit drug,
previous  incarceration, homosexual behavior, anal sex, and
HCV  infection. However, in the multivariate analysis, only
male  gender, increasing age, family history of hepatitis, use
of  illicit drug, and homosexual behavior remained signiﬁ-
cantly  and independently associated with HBV infection in
HIV  positive patients (Table 4). Low education and income
level,  history of surgery and tattooing, shared personal objects,
intravenous illicit drug use, condom use, multiple sex part-
ners  and history of blood transfusion were not statistically
signiﬁcant.
HBV-DNA was  detected in 16 of the 21 HBsAg positive
samples (76.2%) and 13 were successfully sequenced. The phy-
logenetic analysis based on pre-S/S region revealed that the
distribution  of HBV genotypes among these patients was  A
(n  = 1; 7.7%), D (n = 10; 77.0%) and F (n = 2; 15.3%). The geno-
type  A isolated was  from subgenotype A2. Among the 10
samples  classiﬁed as genotype D, 6 were clustered in subgeno-
type  D2 and one with D3. One of the 2 isolated F genotypes
was  subgenotype F2. The phylogenetic tree was  constructed
from  7 patients and reference sequences of HBV subgeno-
types  retrieved from GenBank. The evolutionary history was
inferred  using the Neighbor-Joining method. As seen in Fig. 1,
each genotype clusters together.
HIV-infected patients in Campo Grande, Mato  Grosso do
Positive 95% CIa
n %
21 2.5 1.4–3.5
47 5.5 4.0–7.1
154 18.2 15.6–20.8
222 26.2 23.3–29.3
142 16.7 14.2–19.3
484 57.1 53.7–60.4
848 100.0
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Table 4 – Univariate and multivariate analysis of factors associated with risk of acquiring infection with hepatitis B in
HIV-infected patients in Campo Grande, central-West Region of Brazil, 2013 (n = 706a).
Variable HBV % Odds ratio p Adjusted Odds ratio p
Positive/total (95% CIb) (95% CI)
Gender
Female 60/292 20.5 1.0 1.0
Male 162/414 39.1 2.49 (1.76–3.51) <0.01 1.97 (1.32–2.94) <0.01
Age (years)
≤25  3/37 8.1 1.0 1.0
26–35 28/170 16.5 2.23 (0.64–7.79) 0.30 2.31 (0.63–8.47) 0.21
36–45 83/242 34.3 5.91 (1.76–19.83) <0.01 6.23 (1.77–22.0) <0.01
46–55 71/180 39.4 7.38 (2.18–24.94) <0.01 8.85 (2.48–31.57) <0.01
> 55 37/77 48.1 10.48 (2.97–37.04) <0.01 15.82 (4.2–59.53) <0.01
Partnership –
With a steady partner 78/310 25.2 1.0 1.0
Without a steady partner 144/396 36.4 1.70 (1.22–2.36) <0.01 1.26 (0.86–1.84) 0.23
Education level
University + Secondary 92/285 32.2 1.0 1.0
Primary 114/388 29.3 0.87 (0.62–1.21) 0.47 0.96 (0.64–1.42) 0.82
Illiterate 16/33 48.4 1.97 (0.95–4.08) 0.10 1.66 (0.74–3.72) 0.22
Hepatitis in the Family
No  172/589 29.2 1.0 1.0
Yes 50/117 42.7 1.81 (1.20–2.72) <0.01 2.03 (1.30–3.20) <0.01
Use of illicit drug
No  166/570 29.1 1.0 1.0
Yes 56/136 41.2 1.70 (1.16–2.51) <0.01 1.66 (1.08–2.56) 0.02
Detention
No 181/607 29.8 1.0 1.0
Yes 41/99 41.4 1.66 (1.08–2.57) 0.02 1.08 (0.63–1.83) 0.79
Sexual orientation
Heterosexual 159/581 27.4 1.0 1.0
Homosexual/Bisexual 63/125 50.4 2.70 (1.82–4.00) <0.01 2.67 (1.70–4.22) <0.01
Anal sex
No  154/553 27.8 1.0 1.0
Yes 68/153 44.4 2.07 (1.43–3.00) <0.01 1.11 (0.61–2.03) 0.73
Number of sexual partners in last year
None or 1 150/510 29.4 1.0 1.0
2–5 57/156 36.5 1.38 (0.94–2.01) 0.11 1.08 (0.70–1.68) 0.73
> 5 15/40 37.5 1.44 (0.73–2.80) 0.37 0.78 (0.38–1.64) 0.52
HCV seropositivity
No  198/655 30.2 1.0
Yes 24/51 47.1 2.05 (1.55–3.64) <0.01 1.23 (0.64–2.38) 0.53
a HIV-infected patients with isolate anti-HBs (n = 142) were excluded from risk factors analysis.
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iscussion
IV and HBV have similar routes of transmission, and there-
ore,  HIV positive individuals are at risk for coinfection with
BV.  HIV infection leads to a signiﬁcant change in epidemio-
ogical  proﬁle, natural history and treatment of chronic HBV
nfection  resulting in higher rates of persistence and increas-
ng  liver-related morbidity and mortality.15
The prevalence of serological markers of HBV exposure in
IV-infected  individuals varies according to the geographical
rea  and the risk rates of the studied population. Knowl-
dge  on regional HBV prevalence is important for providers.The  prevalence of HBV infection among HIV-infected patients
measured  in this study (26.2%) was  lower than those reported
in  sub-Saharan Africa (59.8%),16 Chile (46.3%),17 Cuba (45.5%)18
and in different regions of Brazil, which ranges from 30.0% to
55.1%.4,5,7,19,20
The prevalence of HIV-HBV coinfection (2.5%) in the present
study  was lower than those reported in different regions of
Brazil  (5.7%, 8.5%, and 18%).4,5,21 In addition, our results were
in  line with the prevalence of HIV-HBV coinfection from the
state  of Mato Grosso, also located in Central-West Region of
Brazil.20
In the population-based multicentric survey of hepatitis B
infection  conducted in urban area of Central-West Region of
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Fig. 1 – Neighbor-joining phylogenetic tree based on pre S/S gene from 7 Brazilian HIV-HBV coinfected patients (HBC) and
reference sequences representing all known HBV subgenotypes available at the GenBank. The numbers at the nodes
represent the bootstrap support values (% obtained for 1000 replicates).Brazil, the region was  classiﬁed as a low HBV endemic area
based  on the encountered prevalence.22 On the other hand,
remote  sites highly endemic for HBV have been reported in
the  Afro-descendant communities in Central-West, even in
Mato Grosso do Sul state.23,24 Therefore, this low HIV-HBV
coinfection rate could be attributable to the low HBV infection
endemicity found in the urban area of Central-West Region of
Brazil.
Therefore,  HIV-infected patients with isolated anti-HBc
should be vaccinated against HBV.25,26 The inability to detect
HBsAg  in individuals positive for anti-HBc alone can be
attributed  to different factors such as low level of HBV repli-
cation,  HBV genotype variations and mutations in pre-S/S
genomic region, which can affect HBsAg detection by conven-
tional  techniques.27
The vaccination against hepatitis B infection of all people
living  with HIV, with post-vaccination testing and revaccina-
tion  of full series non-responders, is a cornerstone of HBV
prevention.28,29 Only 16.7% of 848 HIV infected participants
had protective anti-HBs titers. In our region, immunization
against hepatitis B was  not routinely offered for all HIV-
infected  individuals to prevent primary HBV infection. The
lack  of response to hepatitis B vaccination among HIV-infectedpatients  may  be because they were not vaccinated or due to
immunologic impairment resulting in decreased response to
the vaccine. Therefore, providing higher and additional doses
of  vaccine or using immunomodulatory agents are methods
to  enhance the immune response in non-responders.28 Also,
a  large number of patients (57.1%) are still susceptible to HBV
infection.  Despite immunization against hepatitis B not being
routinely  offered for all HIV-infected individuals to prevent
primary  HBV infection, these ﬁnding underscore the need to
ensure early vaccination as a means of primary prevention
against HBV infection.
Few  studies on HIV-infected patients with multiple hep-
atitis  viruses have been published to date.30 No HIV-HBV
patients had anti-HDV positivity, conﬁrming that HDV infec-
tion  is infrequent in the Central-West Region of Brazil.20 The
prevalence  of HIV/HBV/HCV in HIV-infected patients is below
3%,  but much  higher than that in the general population.26 In
our  study, the prevalence of HIV/HBV/HCV coinfection (0.1%) is
similar to other rates previously reported (0.1% and 0.3%).31,32
After multivariate analysis, serological evidence of HBV
infection was  signiﬁcantly associated with male gender, age
over  35 years, family history of hepatitis, use of illicit drug and
homosexual  behavior. A predominance of the male gender has
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lso been reported previously in other studies possibly due to
igh-risk behaviors for HBV infection increasing sexual and
ercutaneous exposure.17,19,33 This trend may be explained on
he  basis of the higher rate of injecting drug users (IDU) among
he  males studied (86.6% – data not showed).
Signiﬁcant increase in the seroprevalence of HBV was
bserved among older adults. This ﬁnding was  in line with
revious  studies, which reported that older age was  associated
ith  a higher risk of HBV exposure.18,19,25 History of hepati-
is  in the family was  also strongly associated with serological
arkers of previous exposure to HBV, and probably indicates
hat  most HBV exposure is associated with the patients’ close
ontacts  (e.g. family environment).32
This study also found that the non-intravenous illicit drug
buse  remained signiﬁcantly and independently associated
ith  HBV coinfection. Injection and non-injection drug use
re  identiﬁed as important factors associated with unsafe sex-
al practices, putting illicit drug users at high risk for HBV
nfection  and transmission.19,34
A strong association between homosexual activity and HBV
oinfection  was  also observed, which is in agreement with pre-
ious reports and demonstrates that HBV infection is highly
inked  to sexual intercourse, including men  who have sex with
en  (MSM).4,18,35 Although the majority of HIV-positive Brazil-
ans  become infected through heterosexual sex, MSM still face
 proportionally higher risk. Studies conducted in 10 Brazil-
an  municipalities between 2008 and 2009 estimated MSM are
round 11 times more  likely to become infected with HIV than
eterosexual individuals, with HIV prevalence rates of 12.6%
mong  MSM.36 MSM  should be encouraged to use condoms
uring anal sex in order to reduce the risk of HIV-HBV coin-
ection.
The  molecular characterization of the HBV sequences is
lso  important to establish evolutionary origins and pat-
erns  of viral dispersal.37 Among HBsAg-positive patients, HBV
enotypes  D, F and A were  found. This study supports pre-
ious  ﬁndings that conﬁrm the predominant movement  of
hese  genotypes in the Brazilian population, as well as in our
egion.37–39
The present study has certain limitations. As the study
esign  was  cross-sectional, a causal relationship between
he  time of exposure and subsequent infection could not be
stablished.  However, the study was  conducted in two main
eference  centers of infectious diseases where nearly all of
he  HIV-infected patients are diagnosed and followed-up in
he state of Mato Grosso do Sul, Central-West Region of Brazil.
These  results suggest that people infected with HIV are
xposed  to HBV at a higher rate than the general popula-
ion  and the prevalence of HIV-HBV coinfection in our region
s  lower than that in other regions of Brazil. Male gender,
ncreasing age, family history of hepatitis, use of illicit drug
nd  homosexual contact play an important role in the trans-
ission  of these two viruses. Furthermore, detecting and
mmunizing susceptible individuals and revaccination of HIV-
nfected individuals who did not respond to the standard HBV
accination  schedule is an important strategy for lowering the
ncidence  of HBV infection among HIV-infected individuals.
urther investigations at clinical, molecular and immunolog-
cal  levels to elucidate the interaction of HBV-HIV coinfection
mong  these patients are warranted.
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